Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study

Neurology

Volumn 75, Issue 3, 2010, Pages 208-216

  Takano, R ^a   Misu, T ^a   Takahashi, T ^b   Sato, S ^c   Fujihara, K ^a   Itoyama, Y ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yonezawa National Hospital   (Japan)

^c KOHNAN HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AQUAPORIN 4 ANTIBODY; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN BASIC PROTEIN; NEUROFILAMENT H PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN S100B; UNCLASSIFIED DRUG;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; ASTROCYTE; BEHCET DISEASE; BRAIN ISCHEMIA; BRAIN NERVE CELL; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE CELL LESION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; SENSITIVITY AND SPECIFICITY;

EID: 77954982900     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e2414b     Document Type: Article

References (37)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis op-tica. Lancet Neurol 2007;6:805-815.
2. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460-2468.
3. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127.
4. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinsh-enker BG. The clinical course of neuromyelitis optica (De-vic's syndrome). Neurology 1999;53:1107-1114.
5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
6. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
7. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 2006;209:269-275.
8. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-1234.
9. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuro-myelitis optica from multiple sclerosis. Brain 2007;130: 1194-1205.
10. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-2231.
11. Giovannoni G. Multiple sclerosis cerebrospinal fluid bi-omarkers. Dis Markers 2006;22:187-196.
12. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astro-cytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575-577.
13. Whitaker JN. Myelin encephalitogenic protein fragments in cerebrospinal fluid of persons with multiple sclerosis. Neurology 1977;27:911-920.
14. Cohen SR, Brooks BR, Herndon RM, McKhann GM. A diagnostic index of active demyelination: myelin basic protein in cerebrospinal fluid. Ann Neurol 1980;8:25-31.
15. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neu-romyelitis optica. Neurology 2006;66:1485-1489.
16. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-1243.
17. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25: 5771-5792.
20. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients: The Neuro-Behcet Study Group. Brain 1999;122:2171-2182.
21. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. An ELISA for glial fibrillary acidic protein. J Immunol Methods 2004;287:169-177.
22. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008;205:2473-2481.
23. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730-5737.
24. Kinoshita M, Nakatsuji Y, Moriya M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009;20:508-512.
25. Takano R, Misu T, Takahashi T, Izumiyama M, Fuji-hara K, Itoyama Y. A prominent elevation of glial fibril-lary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 2008;215:55-59.
26. Rosengren LE, Lycke J, Andersen O. Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. J Neurol Sci 1995;133:61-65.
27. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002;125:1462-1473.
28. Vissers JL, Mersch ME, Rosmalen CF, et al. Rapid immu-noassay for the determination of glial fibrillary acidic protein (GFAP) in serum. Clin Chim Acta 2006;366:336-340.
29. Nishiyama H, Knopfel T, Endo S, Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proc Natl Acad Sci USA 2002;99:4037-4042.
30. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-132. (Pubitemid 46152772)
31. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61-76.
32. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 1994;51:197-204.
33. Schipper HM, Liang JJ, Wang E. Quiescent and cycling cell compartments in the senescent and Alzheimer-diseased human brain. Neurology 1993;43:87-94.
34. Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg 2004;106:159-171.
35. Miyazawa I, Nakashima I, Petzold A, Fujihara K, Sato S, Itoyama Y. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007;68:865-867. (Pubitemid 46568541)
36. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis op-tica. Brain 2008;131:3072-3080.
37. Greitz D. Cerebrospinal fluid circulation and associated intracranial dynamics: a radiologic investigation using MR imaging and radionuclide cisternography. Acta Radiol Suppl 1993;386:1-23.